Analyst Consensus ?
ConsensusBuy42 ratings
Bullish3583.3%
Neutral716.7%
Bearish00.0%
FN2 Earnings Intelligence
Thermo Fisher Scientific Inc. analyst ratings
Thermo Fisher Scientific Inc. (TMO) analyst consensus, price targets, and firm-level rating history from FN2 Research.
Analyst 52W Price Targets
$574.3Previous close
$460Low
$618.98Average
$750High
Latest persisted target per named analyst; persisted previous close from FN2's market snapshot as of Aug 1, 2026. Not an FN2 forecast.
Firm-level rating actions
FMP grade actions identify the grading firm, not a named analyst.
| Firm | Rating | Prior rating | Action | Date |
|---|---|---|---|---|
| Piper Sandler | Neutral | Neutral | Maintain | Jul 27, 2026 |
| Morgan Stanley | Overweight | Overweight | Maintain | Jul 27, 2026 |
| RBC Capital | Sector Perform | Sector Perform | Maintain | Jul 24, 2026 |
| Barclays | Overweight | Overweight | Maintain | Jul 24, 2026 |
| Evercore ISI Group | Outperform | Outperform | Maintain | Jul 6, 2026 |
| HSBC | Hold | Buy | Downgrade | Jun 3, 2026 |
| Wells Fargo | Overweight | Overweight | Maintain | May 8, 2026 |
| Stifel | Buy | Buy | Maintain | Apr 24, 2026 |
| Baird | Outperform | Outperform | Maintain | Apr 24, 2026 |
| TD Cowen | Buy | Buy | Maintain | Jan 30, 2026 |
| Citigroup | Buy | Buy | Maintain | Jan 30, 2026 |
| Keybanc | Overweight | Sector Weight | Upgrade | Dec 8, 2025 |
| Argus Research | Buy | Buy | Maintain | Oct 29, 2025 |
| UBS | Neutral | Neutral | Maintain | Oct 23, 2025 |
| Leerink Partners | Outperform | Outperform | Maintain | Oct 22, 2025 |
| JP Morgan | Overweight | Overweight | Maintain | Oct 9, 2025 |
| Raymond James | Outperform | Outperform | Maintain | Jul 24, 2025 |
| Scotiabank | Sector Outperform | Sector Perform | Upgrade | Jul 11, 2025 |
| B of A Securities | Buy | Buy | Maintain | Dec 13, 2024 |
| Bernstein | Market Perform | Market Perform | Maintain | Oct 24, 2024 |
| Deutsche Bank | Buy | Buy | Maintain | Apr 25, 2024 |
| Goldman Sachs | Buy | Buy | Maintain | Apr 10, 2024 |
| Credit Suisse | Outperform | Neutral | Upgrade | Jul 13, 2023 |
| SVB Leerink | Outperform | Outperform | Maintain | Jul 6, 2023 |
| Cowen & Co. | Outperform | Outperform | Maintain | Feb 2, 2023 |
| BTIG | Buy | Buy | Maintain | Feb 2, 2022 |
| Benchmark | Buy | Buy | Maintain | Jul 16, 2021 |
| Needham | Buy | Buy | Maintain | Dec 1, 2020 |
| Atlantic Equities | Overweight | Overweight | Maintain | Sep 30, 2020 |
| Cleveland Research | Buy | Neutral | Upgrade | Jul 15, 2020 |
| Stifel Nicolaus | Buy | Buy | Maintain | Nov 15, 2019 |
| Bank of America | Buy | Buy | Maintain | Feb 1, 2018 |
| BTIG Research | Buy | Buy | Maintain | Jan 5, 2018 |
| Leerink Swann | Outperform | Outperform | Maintain | Oct 9, 2017 |
| Cantor Fitzgerald | Overweight | Overweight | Maintain | May 19, 2017 |
| Jefferies | Hold | Buy | Downgrade | Apr 29, 2016 |
| Avondale Partners | Outperform | Market Outperform | Maintain | Jan 6, 2016 |
| Macquarie | Outperform | Outperform | Maintain | Jul 24, 2014 |
| Janney Capital | Buy | Buy | Maintain | Aug 15, 2013 |
| ISI Group | Buy | Buy | Maintain | Jan 31, 2013 |
| Wallachbeth | Buy | Buy | Maintain | Aug 9, 2012 |
| Mizuho | Neutral | Buy | Downgrade | May 15, 2012 |
Named analyst price targets
Upside is calculated against the persisted previous close $574.3. FMP does not supply a rating on these named-analyst rows.
| Firm | Analyst | 52W target | Price when posted | Upside | Date |
|---|---|---|---|---|---|
| Piper Sandler | Analyst unavailable | $600 | $568.26 | +4.5% | Jul 27, 2026 |
| Morgan Stanley | Analyst unavailable | $650 | $568.26 | +13.2% | Jul 24, 2026 |
| RBC Capital | Dan Leonard | $580 | $561.09 | +1.0% | Jul 24, 2026 |
| Jefferies | Tycho Peterson | $630 | $572.6 | +9.7% | Jul 23, 2026 |
| Evercore ISI | Analyst unavailable | $570 | $511.31 | -0.7% | Jul 6, 2026 |
| Bernstein | Analyst unavailable | $520 | $505.75 | -9.5% | Jun 26, 2026 |
| Piper Sandler | Analyst unavailable | $510 | $482.04 | -11.2% | Jun 11, 2026 |
| HSBC | Sidharth Sahoo | $540 | $482.08 | -6.0% | Jun 3, 2026 |
| RBC Capital | Analyst unavailable | $490 | $448.21 | -14.7% | May 14, 2026 |
| Morgan Stanley | Kallum Titchmarsh | $620 | $472.23 | +8.0% | Apr 27, 2026 |
| Stifel Nicolaus | Daniel Arias | $600 | $467.47 | +4.5% | Apr 24, 2026 |
| Robert W. Baird | Catherine Ramsey Schulte | $639 | $466.7 | +11.3% | Apr 24, 2026 |
| UBS | Analyst unavailable | $615 | $579.86 | +7.1% | Jan 30, 2026 |
| Wells Fargo | Analyst unavailable | $683 | $580.09 | +18.9% | Jan 30, 2026 |
| Robert W. Baird | Analyst unavailable | $653 | $583.12 | +13.7% | Jan 30, 2026 |
| Barclays | Analyst unavailable | $650 | $592.16 | +13.2% | Jan 30, 2026 |
| Stifel Nicolaus | Daniel Arias | $700 | $606.5 | +21.9% | Jan 9, 2026 |
| Evercore ISI | Vijay Kumar | $650 | $605.83 | +13.2% | Jan 5, 2026 |
| Wells Fargo | Analyst unavailable | $675 | $571.99 | +17.5% | Dec 15, 2025 |
| Goldman Sachs | Evie Koslosky | $685 | $568.21 | +19.3% | Dec 9, 2025 |
| KeyBanc | Paul Knight | $750 | $572.77 | +30.6% | Dec 7, 2025 |
| Argus Research | Analyst unavailable | $610 | $570.82 | +6.2% | Oct 29, 2025 |
| Morgan Stanley | Analyst unavailable | $656 | $563.28 | +14.2% | Oct 28, 2025 |
| UBS | Analyst unavailable | $590 | $571.68 | +2.7% | Oct 23, 2025 |
| Barclays | Analyst unavailable | $625 | $567.2 | +8.8% | Oct 23, 2025 |
| Leerink Partners | Analyst unavailable | $580 | $567.2 | +1.0% | Oct 22, 2025 |
| Redburn Partners | Analyst unavailable | $575 | $536.19 | +0.1% | Oct 8, 2025 |
| Redburn Partners | Analyst unavailable | $580 | $539.17 | +1.0% | Oct 8, 2025 |
| Barclays | Luke Sergott | $585 | $530.73 | +1.9% | Oct 2, 2025 |
| RBC Capital | Conor McNamara | $561 | $487.53 | -2.3% | Sep 2, 2025 |
| UBS | Dan Leonard | $460 | $426.17 | -19.9% | Jul 8, 2025 |
| Scotiabank | Analyst unavailable | $605 | $424.24 | +5.3% | Apr 25, 2025 |
| Goldman Sachs | Matthew Sykes | $610 | $431.64 | +6.2% | Apr 23, 2025 |
| RBC Capital | Conor McNamara | $693 | $597.75 | +20.7% | Jan 31, 2025 |
| Evercore ISI | Vijay Kumar | $585 | $522.57 | +1.9% | Jan 2, 2025 |
| Robert W. Baird | Catherine Schulte | $622 | $576.49 | +8.3% | Oct 24, 2024 |
| Barclays | Luke Sergott | $610 | $570.92 | +6.2% | Oct 23, 2024 |
| Evercore ISI | Vijay Kumar | $630 | $618.57 | +9.7% | Oct 1, 2024 |
| Stifel Nicolaus | Daniel Arias | $680 | $620.25 | +18.4% | Sep 20, 2024 |
| Robert W. Baird | Catherine Schulte | $632 | $620.25 | +10.0% | Sep 20, 2024 |
| Citigroup | Patrick Donnelly | $620 | $617.1 | +8.0% | Sep 19, 2024 |
| Deutsche Bank | Justin Bowers | $630 | $609.41 | +9.7% | Sep 18, 2024 |
| Bank of America Securities | Derik de Bruin | $675 | $611.17 | +17.5% | Sep 16, 2024 |
| Raymond James | Andrew Cooper | $660 | $593.86 | +14.9% | Jul 25, 2024 |
| Barclays | Luke Sergott | $600 | $550.78 | +4.5% | Jun 28, 2024 |
| HSBC | Sidharth Sahoo | $670 | $576.89 | +16.7% | Apr 30, 2024 |
| Deutsche Bank | Justin Bowers | $610 | $577.39 | +6.2% | Apr 25, 2024 |
| Barclays | Luke Sergott | $615 | $577.39 | +7.1% | Apr 25, 2024 |
| Robert W. Baird | Catherine Schulte | $670 | $531.65 | +16.7% | Dec 28, 2023 |
| Raymond James | Andrew Cooper | $530 | $444.46 | -7.7% | Oct 26, 2023 |
| Credit Suisse | Thermo Fisher | $620 | $525.63 | +8.0% | Jul 13, 2023 |
| Cowen & Co. | Analyst unavailable | $711 | $591.95 | +23.8% | Feb 2, 2023 |
| Citigroup | Analyst unavailable | $700 | $589.73 | +21.9% | Feb 2, 2023 |
| Barclays | Analyst unavailable | $660 | $587.36 | +14.9% | Feb 2, 2023 |
| Leerink Partners | Analyst unavailable | $630 | $587.36 | +9.7% | Feb 2, 2023 |
| Leerink Partners | Analyst unavailable | $620 | $532.88 | +8.0% | Jan 6, 2023 |
| Wells Fargo | Analyst unavailable | $505 | $553.18 | -12.1% | Jan 3, 2023 |
| Deutsche Bank | Analyst unavailable | $620 | $571.38 | +8.0% | Dec 14, 2022 |
| RBC Capital | Analyst unavailable | $661 | $550.53 | +15.1% | Dec 7, 2022 |
| Barclays | Analyst unavailable | $570 | $540.03 | -0.7% | Nov 29, 2022 |
| Barclays | Analyst unavailable | $595 | $569.4 | +3.6% | Sep 12, 2022 |
| Barclays | Luke Sergott | $685 | $587.98 | +19.3% | Aug 4, 2022 |
| Morgan Stanley | Analyst unavailable | $678 | $606.24 | +18.1% | Jul 29, 2022 |
| Leerink Partners | Analyst unavailable | $650 | $597.64 | +13.2% | Jul 29, 2022 |
| Barclays | Analyst unavailable | $630 | $530.93 | +9.7% | Jul 13, 2022 |
| Morgan Stanley | Analyst unavailable | $670 | $563.79 | +16.7% | Apr 29, 2022 |
| Wells Fargo | Analyst unavailable | $525 | $561.28 | -8.6% | Apr 25, 2022 |
| Morgan Stanley | Tejas Savant | $700 | $619.47 | +21.9% | Oct 28, 2021 |
| Benchmark Co. | Robert Wasserman | $650 | $611.7 | +13.2% | Oct 27, 2021 |
| Goldman Sachs | Matthew Sykes | $690 | $607.64 | +20.1% | Sep 23, 2021 |
| J.P. Morgan | Tycho Peterson | $700 | $589.63 | +21.9% | Sep 20, 2021 |
| Bank of America Securities | Derik De Bruin | $670 | $589.63 | +16.7% | Sep 20, 2021 |
| KeyBanc | Paul Knight | $710 | $589.63 | +23.6% | Sep 20, 2021 |
| Jefferies | Brandon Couillard | $540 | $589.63 | -6.0% | Sep 20, 2021 |
| Argus Research | David Toung | $600 | $538.11 | +4.5% | Aug 4, 2021 |
Track every rating change on TMO the moment it posts. Free to start.
Start free